Question special

Let's say Dr Yanoff and I share a 76 year-old female patient as part of a Swedish-inspired "fracture chain" clinic. Our patient has a T-score of -2.9 who has severe GERD and hypercholesterolemia. She has a history of a distal radius fracture but was never on anti-osteoporotic therapy under her previous providers. She had radiation therapy for a malignancy many years ago, and recent cancer screening is negative. We are considering romosozumab for her. Is she an ideal candidate, and how should we advise her during shared decision making?